- Markets
- Software Services
- SPARC
SPARC
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Sun Pharma Advanced Research Signs Binding LOI With UCSF And Tiller Therapeutics
Dec 17 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:
SPARC SIGNS BINDING LOI WITH UCSF AND TILLER THERAPEUTICS
SPARC TO RECEIVE 55% EQUITY IN TILLER THERAPEUTICS
LOI FOR PRE-CLINICAL ONCOLOGY ASSET, ASSOCIATED INTELLECTUAL PROPERTY
Source text: ID:nBSE9Cy21m
Further company coverage: SPRC.NS
(([email protected];;))
Dec 17 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:
SPARC SIGNS BINDING LOI WITH UCSF AND TILLER THERAPEUTICS
SPARC TO RECEIVE 55% EQUITY IN TILLER THERAPEUTICS
LOI FOR PRE-CLINICAL ONCOLOGY ASSET, ASSOCIATED INTELLECTUAL PROPERTY
Source text: ID:nBSE9Cy21m
Further company coverage: SPRC.NS
(([email protected];;))
India's Sun Pharma Advanced Research falls after Q2 loss widens
** Shares of Sun Pharma Advanced Research Co SPRC.NS fall 4.7% to 205.80 rupees
** The clinical-stage biopharmaceutical co's Q2 consol loss widened to 1.07 bln rupees ($12.7 mln) vs loss of 864.2 mln rupees a year ago, revenue down 39% Y/Y
** SPRC set to snap five-session winning streak
** Trading vols 1.9x the 30-day average
** Stock down ~28% YTD
($1 = 84.1125 Indian rupees)
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of Sun Pharma Advanced Research Co SPRC.NS fall 4.7% to 205.80 rupees
** The clinical-stage biopharmaceutical co's Q2 consol loss widened to 1.07 bln rupees ($12.7 mln) vs loss of 864.2 mln rupees a year ago, revenue down 39% Y/Y
** SPRC set to snap five-session winning streak
** Trading vols 1.9x the 30-day average
** Stock down ~28% YTD
($1 = 84.1125 Indian rupees)
(Reporting by Vijay Malkar)
(([email protected];))
UPDATE 7-Consumer groups ask FTC to block Novo Holdings-Catalent deal
Consumer groups and unions express competition concerns to FTC
Deal could limit options for competitors developing GLP-1 drugs
Concerns also raised about impact on gene therapy manufacturing
Adds Novo Holdings comment in paragraph 7
By Jody Godoy and Maggie Fick
NEW YORK, Oct 18 (Reuters) - U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk NOVOb.CO, from acquiring contract drug manufacturer Catalent CTLT.N, saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies.
U.S. Public Interest Research Group, Service Employees International Union (SEIU) and others expressed concerns in a letter to the FTC about the $16.5 billion deal, which Novo Holdings has said would boost supply of Wegovy, Novo's blockbuster GLP-1 injectable weight-loss drug.
Last week, U.S. Senator Elizabeth Warren, a Democrat, called on the FTC to look closely at the deal over similar concerns.
The deal could constrain options for competitors such as Amgen AMGN.O, Pfizer PFE.N, Roche ROG.S, and AstraZeneca AZN.L, who are reportedly developing their own GLP-1 drugs, the groups said.
"Because of the proposed acquisition, there is a real question of whether these future rivals to Novo will be able to secure the expertise to bring the product to market and have available and qualified capacity to manufacture these products when they commercially launch," the groups said.
Viking Therapeutics VKTX.O, Structure Therapeutics GPCR.O and Sun Pharma SUN.NS also have GLP-1 drugs in development and could be affected, the groups said.
Novo Holdings, in a statement to Reuters on Friday in response to the consumer groups' letter, said: "We remain confident in the pro-competitive rationale for this transaction and are committed to realizing the benefits it will bring to customers, and patients, and the local communities which Catalent now serves."
A Catalent spokesperson reiterated the company's position on the deal in a statement on Friday to Reuters in response to the letter: "Novo Holdings’ pending acquisition of Catalent will further strengthen Catalent’s ability to deliver better outcomes for our customers and the patients they serve."
A Viking spokesperson declined to comment. A Roche spokesperson declined to comment on the letter, but said that the drugmaker has secured near-term supplies for its clinical trials of the GLP-1 drugs it is developing. Roche plans to manage the scaling up of commercial production "by using a mix of in-house and external manufacturing", the spokesperson said.
The other companies did not immediately respond to requests for comment on Thursday.
According to the terms of the deal, Novo Holdings would sell three of Catalent's factories, where injection pens are filled in sterile conditions, in Italy, Belgium and the United States, on to Novo Nordisk for $11 billion.
Novo Nordisk has said it is committed to honoring existing contracts at the plants, and that it is not aware of any competitive GLP-1 products being manufactured for commercial sale at the three sites.
"We have and will continue to work closely with the FTC and EU regulators as intended under the law. We still expect the transaction to close toward the end of the calendar year," Novo Nordisk said in its response to the consumer groups' letter.
The groups, which included Consumer Action, diabetes group Beta Cell Action, Doctors for America and the American Federation of State, County and Municipal Employees (AFSCME) union, also expressed concern that Novo Holding's ownership could affect Catalent's capacity to manufacture gene therapies.
AFSCME represents around 1.6 million public sector workers, and SEIU has around 2 million members who work in healthcare, the public sector and property services.
Ten consumer groups had signed on to the letter on Thursday afternoon.
"The competitive concerns here go far beyond existing drugs. We believe the commission should look at the impact on future therapies including gene therapy," said David Balto, the antitrust lawyer who represents the groups and drafted the letter.
The letter mentioned Catalent's contracts with Sarepta Therapeutics SRPT.O, to produce its gene therapy Elevidys, and with Novartis NOVN.S, to produce its gene therapy Zolgensma. The Catalent facilities involved are separate from the three factories that Novo Holdings plans to sell on to Novo Nordisk.
Sarepta does not anticipate any impact from the Catalent acquisition, spokesperson Tracy Sorrentino said on Thursday. Sarepta's contract with Catalent runs through 2028.
A Novartis spokesperson said on Thursday that Zolgensma is no longer manufactured at any Catalent facility.
(Reporting by Jody Godoy in New York and Maggie Fick in London; Editing by Tomasz Janowski, Louise Heavens and Mark Potter)
(([email protected];))
Consumer groups and unions express competition concerns to FTC
Deal could limit options for competitors developing GLP-1 drugs
Concerns also raised about impact on gene therapy manufacturing
Adds Novo Holdings comment in paragraph 7
By Jody Godoy and Maggie Fick
NEW YORK, Oct 18 (Reuters) - U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk NOVOb.CO, from acquiring contract drug manufacturer Catalent CTLT.N, saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies.
U.S. Public Interest Research Group, Service Employees International Union (SEIU) and others expressed concerns in a letter to the FTC about the $16.5 billion deal, which Novo Holdings has said would boost supply of Wegovy, Novo's blockbuster GLP-1 injectable weight-loss drug.
Last week, U.S. Senator Elizabeth Warren, a Democrat, called on the FTC to look closely at the deal over similar concerns.
The deal could constrain options for competitors such as Amgen AMGN.O, Pfizer PFE.N, Roche ROG.S, and AstraZeneca AZN.L, who are reportedly developing their own GLP-1 drugs, the groups said.
"Because of the proposed acquisition, there is a real question of whether these future rivals to Novo will be able to secure the expertise to bring the product to market and have available and qualified capacity to manufacture these products when they commercially launch," the groups said.
Viking Therapeutics VKTX.O, Structure Therapeutics GPCR.O and Sun Pharma SUN.NS also have GLP-1 drugs in development and could be affected, the groups said.
Novo Holdings, in a statement to Reuters on Friday in response to the consumer groups' letter, said: "We remain confident in the pro-competitive rationale for this transaction and are committed to realizing the benefits it will bring to customers, and patients, and the local communities which Catalent now serves."
A Catalent spokesperson reiterated the company's position on the deal in a statement on Friday to Reuters in response to the letter: "Novo Holdings’ pending acquisition of Catalent will further strengthen Catalent’s ability to deliver better outcomes for our customers and the patients they serve."
A Viking spokesperson declined to comment. A Roche spokesperson declined to comment on the letter, but said that the drugmaker has secured near-term supplies for its clinical trials of the GLP-1 drugs it is developing. Roche plans to manage the scaling up of commercial production "by using a mix of in-house and external manufacturing", the spokesperson said.
The other companies did not immediately respond to requests for comment on Thursday.
According to the terms of the deal, Novo Holdings would sell three of Catalent's factories, where injection pens are filled in sterile conditions, in Italy, Belgium and the United States, on to Novo Nordisk for $11 billion.
Novo Nordisk has said it is committed to honoring existing contracts at the plants, and that it is not aware of any competitive GLP-1 products being manufactured for commercial sale at the three sites.
"We have and will continue to work closely with the FTC and EU regulators as intended under the law. We still expect the transaction to close toward the end of the calendar year," Novo Nordisk said in its response to the consumer groups' letter.
The groups, which included Consumer Action, diabetes group Beta Cell Action, Doctors for America and the American Federation of State, County and Municipal Employees (AFSCME) union, also expressed concern that Novo Holding's ownership could affect Catalent's capacity to manufacture gene therapies.
AFSCME represents around 1.6 million public sector workers, and SEIU has around 2 million members who work in healthcare, the public sector and property services.
Ten consumer groups had signed on to the letter on Thursday afternoon.
"The competitive concerns here go far beyond existing drugs. We believe the commission should look at the impact on future therapies including gene therapy," said David Balto, the antitrust lawyer who represents the groups and drafted the letter.
The letter mentioned Catalent's contracts with Sarepta Therapeutics SRPT.O, to produce its gene therapy Elevidys, and with Novartis NOVN.S, to produce its gene therapy Zolgensma. The Catalent facilities involved are separate from the three factories that Novo Holdings plans to sell on to Novo Nordisk.
Sarepta does not anticipate any impact from the Catalent acquisition, spokesperson Tracy Sorrentino said on Thursday. Sarepta's contract with Catalent runs through 2028.
A Novartis spokesperson said on Thursday that Zolgensma is no longer manufactured at any Catalent facility.
(Reporting by Jody Godoy in New York and Maggie Fick in London; Editing by Tomasz Janowski, Louise Heavens and Mark Potter)
(([email protected];))
Consumer groups ask FTC to block Novo Holdings-Catalent deal
Consumer groups and unions express competition concerns to FTC
Deal could limit options for competitors developing GLP-1 drugs
Concerns also raised about impact on gene therapy manufacturing
By Jody Godoy, Maggie Fick
NEW YORK, Oct 17 (Reuters) - Five U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Nordisk's NOVOb.CO controlling shareholder from acquiring contract drug manufacturer Catalent CTLT.N, saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies.
U.S. Public Interest Research Group, Service Employees International Union (SEIU) and others expressed concerns in a letter to the FTC about the $16.5 billion deal, which Novo Holdings has said would boost supply of Wegovy, Novo's blockbuster GLP-1 injectable weight loss drug.
Last week, U.S. Senator Elizabeth Warren, a Democrat, called on the FTC to look closely at the deal over similar concerns.
The deal could constrain options for competitors such as Amgen AMGN.O, Pfizer PFE.N, Roche ROG.S, and AstraZeneca AZN.L, who are reportedly developing their own GLP-1 drugs, the groups said.
""Because of the proposed acquisition, there is a real question of whether these future rivals to Novo will be able to secure the expertise to bring the product to market and have available and qualified capacity to manufacture these products when they commercially launch," the groups said.
Viking Therapeutics VKTX.O, Structure Therapeutics GPCR.O and Sun Pharma SUN.NS also have GLP-1 drugs in development and could be affected, the groups said.
According to the terms of the deal, Novo Holdings would sell three of Catalent's factories, where injection pens are filled in sterile conditions, in Italy, Belgium and the United States, on to Novo Nordisk for $11 billion.
Novo Nordisk has said it is committed to honoring existing contracts at the plants, and that it is not aware of any competitive GLP-1 products being manufactured for commercial sale at the three sites.
The groups, which included Consumer Action, Doctors for America and the American Federation of State, County and Municipal Employees (AFSCME) union, also expressed concern that Novo Holding's ownership could affect Catalent's capacity to manufacture gene therapies.
AFSCME represents around 1.6 million public sector workers, and SEIU has around 2 million members who work in healthcare, the public sector and property services.
"The competitive concerns here go far beyond existing drugs. We believe the commission should look at the impact on future therapies including gene therapy," said David Balto, the antitrust lawyer who represents the groups and drafted the letter.
The letter mentioned Catalent's contracts with Sarepta Therapeutics SRPT.O, to produce its gene therapy Elevidys, and with Novartis NOVN.S, to produce its gene therapy Zolgensma. The Catalent facilities producing these therapies are separate from the three factories that Novo Holdings plans to sell on to Novo Nordisk.
(Reporting by Jody Godoy in New York and Maggie Fick in London; Editing by Nick Zieminski)
(([email protected];))
Consumer groups and unions express competition concerns to FTC
Deal could limit options for competitors developing GLP-1 drugs
Concerns also raised about impact on gene therapy manufacturing
By Jody Godoy, Maggie Fick
NEW YORK, Oct 17 (Reuters) - Five U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Nordisk's NOVOb.CO controlling shareholder from acquiring contract drug manufacturer Catalent CTLT.N, saying the deal threatens competition in weight loss drugs and cutting-edge gene therapies.
U.S. Public Interest Research Group, Service Employees International Union (SEIU) and others expressed concerns in a letter to the FTC about the $16.5 billion deal, which Novo Holdings has said would boost supply of Wegovy, Novo's blockbuster GLP-1 injectable weight loss drug.
Last week, U.S. Senator Elizabeth Warren, a Democrat, called on the FTC to look closely at the deal over similar concerns.
The deal could constrain options for competitors such as Amgen AMGN.O, Pfizer PFE.N, Roche ROG.S, and AstraZeneca AZN.L, who are reportedly developing their own GLP-1 drugs, the groups said.
""Because of the proposed acquisition, there is a real question of whether these future rivals to Novo will be able to secure the expertise to bring the product to market and have available and qualified capacity to manufacture these products when they commercially launch," the groups said.
Viking Therapeutics VKTX.O, Structure Therapeutics GPCR.O and Sun Pharma SUN.NS also have GLP-1 drugs in development and could be affected, the groups said.
According to the terms of the deal, Novo Holdings would sell three of Catalent's factories, where injection pens are filled in sterile conditions, in Italy, Belgium and the United States, on to Novo Nordisk for $11 billion.
Novo Nordisk has said it is committed to honoring existing contracts at the plants, and that it is not aware of any competitive GLP-1 products being manufactured for commercial sale at the three sites.
The groups, which included Consumer Action, Doctors for America and the American Federation of State, County and Municipal Employees (AFSCME) union, also expressed concern that Novo Holding's ownership could affect Catalent's capacity to manufacture gene therapies.
AFSCME represents around 1.6 million public sector workers, and SEIU has around 2 million members who work in healthcare, the public sector and property services.
"The competitive concerns here go far beyond existing drugs. We believe the commission should look at the impact on future therapies including gene therapy," said David Balto, the antitrust lawyer who represents the groups and drafted the letter.
The letter mentioned Catalent's contracts with Sarepta Therapeutics SRPT.O, to produce its gene therapy Elevidys, and with Novartis NOVN.S, to produce its gene therapy Zolgensma. The Catalent facilities producing these therapies are separate from the three factories that Novo Holdings plans to sell on to Novo Nordisk.
(Reporting by Jody Godoy in New York and Maggie Fick in London; Editing by Nick Zieminski)
(([email protected];))
Sun Pharma Advanced Research Says Cessation Of Chetan Rajpara As Chief Financial Officer
June 5 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:
CESSATION OF CHETAN RAJPARA AS CHIEF FINANCIAL OFFICER
Source text for Eikon: ID:nNSE5FqJMQ
Further company coverage: SPRC.NS
(([email protected];;))
June 5 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:
CESSATION OF CHETAN RAJPARA AS CHIEF FINANCIAL OFFICER
Source text for Eikon: ID:nNSE5FqJMQ
Further company coverage: SPRC.NS
(([email protected];;))
Sun Pharma Advanced Research Says Chetan Rajpara Resigns As CFO
May 24 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:
SUN PHARMA ADVANCED RESEARCH - CHETAN RAJPARA RESIGNS AS CFO
Source text for Eikon: [ID:]
Further company coverage: SPRC.NS
(([email protected];;))
May 24 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:
SUN PHARMA ADVANCED RESEARCH - CHETAN RAJPARA RESIGNS AS CFO
Source text for Eikon: [ID:]
Further company coverage: SPRC.NS
(([email protected];;))
India's Sun Pharma Advanced slumps after drug trial for early Parkinson's patients fails
** Shares of Sun Pharma Advanced Research SPRC.NS down exchange-allowed maximum of 5% to 429.7 rupees
** The bio-pharma firm's study on using Vodobatinib drug on early Parkinson's patients did not show any benefits
** Stock has been trading above its 200-day simple moving avg since June 2023
** Including session's drop, shares up ~50% YTD
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364;))
** Shares of Sun Pharma Advanced Research SPRC.NS down exchange-allowed maximum of 5% to 429.7 rupees
** The bio-pharma firm's study on using Vodobatinib drug on early Parkinson's patients did not show any benefits
** Stock has been trading above its 200-day simple moving avg since June 2023
** Including session's drop, shares up ~50% YTD
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364;))
India's Sun Pharma Advanced Research hits upper circuit after block deals
** Shares of bio-pharma co Sun Pharma Advanced Research SPRC.NS rise as much as 10% to hit upper circuit at 423.35 rupees
** Stock hits highest level since June 15, 2018
** Over 500,000 shares traded in two separate block deals priced between 422.80 and 423.35 rupees apiece - LSEG
** More than 5.6 mln shares change hands by 12:34 p.m. IST, 1.7x of 30-day avg
** Stock has been active this week with more than 5 mln shares trading daily in four out of five sessions compared with 10 sessions in whole of 2023
** Stock has risen 47.6% so far this week, best weekly gains since January 2015
** In 2023, stock rose 37.5%, best yearly performance since 2021
(Reporting by Ashish Chandra in Bengaluru)
(([email protected] (+91 7982114624))
** Shares of bio-pharma co Sun Pharma Advanced Research SPRC.NS rise as much as 10% to hit upper circuit at 423.35 rupees
** Stock hits highest level since June 15, 2018
** Over 500,000 shares traded in two separate block deals priced between 422.80 and 423.35 rupees apiece - LSEG
** More than 5.6 mln shares change hands by 12:34 p.m. IST, 1.7x of 30-day avg
** Stock has been active this week with more than 5 mln shares trading daily in four out of five sessions compared with 10 sessions in whole of 2023
** Stock has risen 47.6% so far this week, best weekly gains since January 2015
** In 2023, stock rose 37.5%, best yearly performance since 2021
(Reporting by Ashish Chandra in Bengaluru)
(([email protected] (+91 7982114624))
Sun Pharma Canada Launches (PR)ABSORICA LD For Treatment Of Severe Acne
Dec 4 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:
SUN PHARMA CANADA LAUNCHES (PR)ABSORICA LD® (ISOTRETINOIN CAPSULES) FOR TREATMENT OF SEVERE ACNE
Source text for Eikon: ID:nCNWlk5tYa
Further company coverage: SPRC.NS
(([email protected];))
Dec 4 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:
SUN PHARMA CANADA LAUNCHES (PR)ABSORICA LD® (ISOTRETINOIN CAPSULES) FOR TREATMENT OF SEVERE ACNE
Source text for Eikon: ID:nCNWlk5tYa
Further company coverage: SPRC.NS
(([email protected];))
India's Sun Pharma Advanced Research rises to over 1.5-year high
** Shares of Sun Pharma Advanced Research SPRC.NS rise as much as 8% to 277.85 rupees, highest since April 22, 2022
** Stock on track to post highest monthly gain since May 2021, if trends hold
** Stock has been above its 50-day, 100-day, and 200-day simple moving avgs of since Nov. 9, indicating bullish sentiment
** Trading vol is 5.1x the 30-day daily avg, tops 6 mln for the first time since Nov. 9
** SRPC traded most since Aug. 30
** Stock up 7% as of 10:47 a.m. IST, extending YTD gains to ~32%
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected] ;))
** Shares of Sun Pharma Advanced Research SPRC.NS rise as much as 8% to 277.85 rupees, highest since April 22, 2022
** Stock on track to post highest monthly gain since May 2021, if trends hold
** Stock has been above its 50-day, 100-day, and 200-day simple moving avgs of since Nov. 9, indicating bullish sentiment
** Trading vol is 5.1x the 30-day daily avg, tops 6 mln for the first time since Nov. 9
** SRPC traded most since Aug. 30
** Stock up 7% as of 10:47 a.m. IST, extending YTD gains to ~32%
(Reporting by Anuran Sadhu in Bengaluru)
(([email protected] ;))
India's Sun Pharma Advanced Research up on getting Alopecia drug licence
** Shares of Sun Pharma Advanced Research Company SPRC.NS up as much as 7.67% to 247.15 rupees, their highest since Sept. 15
** Bio-pharma co hits sharpest intraday pct gain since Oct. 18
** SPRC enters into an licence agreement with Johns Hopkins University and The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences
** Agreement to exclusively license SCD-153 Alopecia Areata drug
** About 3.3 mln shares traded as of 12:07 p.m. IST, 4.7 the 30-day average
** Stock last up 5.1%, extending YTD gains to ~15%
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364;))
** Shares of Sun Pharma Advanced Research Company SPRC.NS up as much as 7.67% to 247.15 rupees, their highest since Sept. 15
** Bio-pharma co hits sharpest intraday pct gain since Oct. 18
** SPRC enters into an licence agreement with Johns Hopkins University and The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences
** Agreement to exclusively license SCD-153 Alopecia Areata drug
** About 3.3 mln shares traded as of 12:07 p.m. IST, 4.7 the 30-day average
** Stock last up 5.1%, extending YTD gains to ~15%
(Reporting by Manvi Pant in Bengaluru)
(([email protected]; +918447554364;))
Sun Pharma Advanced Research - Incorporated Unit In Delaware, Us
Sept 26 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:
INCORPORATED UNIT IN DELAWARE, US
COST OF ACQUISITION $50,000
Source text for Eikon: ID:nBSEc4DkjC
Further company coverage: SPRC.NS
(([email protected];))
Sept 26 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:
INCORPORATED UNIT IN DELAWARE, US
COST OF ACQUISITION $50,000
Source text for Eikon: ID:nBSEc4DkjC
Further company coverage: SPRC.NS
(([email protected];))
India's Sun Pharma Advanced Research up on US FDA boost for glaucoma drug
** Shares of Sun Pharma Advanced Research Co SPRC.NS rise as much as 4.5% to 230.9 rupees
** Co said on Thurs that US FDA issued a Complete Response Letter for application of glaucoma treatment, PDP-716
** Says FDA did not raise any issues with PDP-176's clinical efficacy or safety and no additional data or trials requested
** Trading vol already at 0.5X the 30-day daily avg as of 9:38 a.m. IST
** Stock up almost 6% YTD as of last close
(Reporting by Varun Vyas in Bengaluru)
** Shares of Sun Pharma Advanced Research Co SPRC.NS rise as much as 4.5% to 230.9 rupees
** Co said on Thurs that US FDA issued a Complete Response Letter for application of glaucoma treatment, PDP-716
** Says FDA did not raise any issues with PDP-176's clinical efficacy or safety and no additional data or trials requested
** Trading vol already at 0.5X the 30-day daily avg as of 9:38 a.m. IST
** Stock up almost 6% YTD as of last close
(Reporting by Varun Vyas in Bengaluru)
Sun Pharma Advanced Research Says FDA Issues Complete Response Letter For Pdp-716 NDA
July 13 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:
FDA ISSUES COMPLETE RESPONSE LETTER FOR PDP-716 NDA DUE TO INSPECTION FINDINGS AT 3RD-PARTY API MANUFACTURING FACILITY
NO ISSUES WITH CLINICAL EFFICACY OR SAFETY WERE IDENTIFIED IN CRL
NO ADDITIONAL CLINICAL DATA OR TRIALS HAVE BEEN REQUESTED
Further company coverage: SPRC.NS
(([email protected];))
July 13 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:
FDA ISSUES COMPLETE RESPONSE LETTER FOR PDP-716 NDA DUE TO INSPECTION FINDINGS AT 3RD-PARTY API MANUFACTURING FACILITY
NO ISSUES WITH CLINICAL EFFICACY OR SAFETY WERE IDENTIFIED IN CRL
NO ADDITIONAL CLINICAL DATA OR TRIALS HAVE BEEN REQUESTED
Further company coverage: SPRC.NS
(([email protected];))
India's Sun Pharma Advanced Research March-Quarter Loss Widens
May 22 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:
INDIA'S SUN PHARMA ADVANCED RESEARCH MARCH-QUARTER LOSS 819.9 MILLION RUPEES VERSUS LOSS 710.5 MILLION RUPEES
SUN PHARMA ADVANCED RESEARCH MARCH-QUARTER REVENUE FROM OPERATIONS 476.9 MILLION RUPEES VERSUS 252.4 MILLION RUPEES
SUN PHARMA ADVANCED RESEARCH - SEEKING APPROVAL FROM SHAREHOLDERS TO RAISE FUNDS FOR UPTO 18 BILLION RUPEES
Source text for Eikon: ID:nBSE6K50B2
Further company coverage: SPRC.NS
(([email protected];))
May 22 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:
INDIA'S SUN PHARMA ADVANCED RESEARCH MARCH-QUARTER LOSS 819.9 MILLION RUPEES VERSUS LOSS 710.5 MILLION RUPEES
SUN PHARMA ADVANCED RESEARCH MARCH-QUARTER REVENUE FROM OPERATIONS 476.9 MILLION RUPEES VERSUS 252.4 MILLION RUPEES
SUN PHARMA ADVANCED RESEARCH - SEEKING APPROVAL FROM SHAREHOLDERS TO RAISE FUNDS FOR UPTO 18 BILLION RUPEES
Source text for Eikon: ID:nBSE6K50B2
Further company coverage: SPRC.NS
(([email protected];))
Sun Pharma Advanced Research To Also Consider Proposals For Raising Funds
May 17 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:
WILL ALSO CONSIDER PROPOSALS FOR RAISING FUNDS
Source text for Eikon: ID:nBSE35P4cT
Further company coverage: SPRC.NS
(([email protected];))
May 17 (Reuters) - Sun Pharma Advanced Research Co Ltd SPRC.NS:
WILL ALSO CONSIDER PROPOSALS FOR RAISING FUNDS
Source text for Eikon: ID:nBSE35P4cT
Further company coverage: SPRC.NS
(([email protected];))
Events:
Rights
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Sun Pharma Adv. Res do?
SPARC is a clinical stage bio-pharmaceutical company specializing in pharmaceutical research and development to create innovative therapeutics and drug delivery systems for enhancing patient care globally.
Who are the competitors of Sun Pharma Adv. Res?
Sun Pharma Adv. Res major competitors are Dishman Carbogen Amc, Zenotech Laboratorie, Vivo Bio Tech, Jeevan Scientific, Syngene Internation., Hikal, Suven Life Sciences. Market Cap of Sun Pharma Adv. Res is ₹4,869 Crs. While the median market cap of its peers are ₹2,754 Crs.
Is Sun Pharma Adv. Res financially stable compared to its competitors?
Sun Pharma Adv. Res seems to be less financially stable compared to its competitors. Altman Z score of Sun Pharma Adv. Res is 5.08 and is ranked 4 out of its 8 competitors.
Does Sun Pharma Adv. Res pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Sun Pharma Adv. Res latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Sun Pharma Adv. Res allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Capital Work in Progress, Inventory, Accounts Receivable, Short Term Loans & Advances
How strong is Sun Pharma Adv. Res balance sheet?
Balance sheet of Sun Pharma Adv. Res is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Sun Pharma Adv. Res improving?
No, profit is decreasing. The profit of Sun Pharma Adv. Res is -₹388.53 Crs for TTM, -₹387.21 Crs for Mar 2024 and -₹222.58 Crs for Mar 2023.
Is the debt of Sun Pharma Adv. Res increasing or decreasing?
Yes, The debt of Sun Pharma Adv. Res is increasing. Latest debt of Sun Pharma Adv. Res is ₹83.08 Crs as of Sep-24. This is greater than Mar-24 when it was -₹263.66 Crs.
Is Sun Pharma Adv. Res stock expensive?
There is insufficient historical data to gauge this. Latest PE of Sun Pharma Adv. Res is 0
Has the share price of Sun Pharma Adv. Res grown faster than its competition?
Sun Pharma Adv. Res has given lower returns compared to its competitors. Sun Pharma Adv. Res has grown at ~-13.48% over the last 7yrs while peers have grown at a median rate of 1.25%
Is the promoter bullish about Sun Pharma Adv. Res?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Sun Pharma Adv. Res is 65.67% and last quarter promoter holding is 65.67%.
Are mutual funds buying/selling Sun Pharma Adv. Res?
The mutual fund holding of Sun Pharma Adv. Res is increasing. The current mutual fund holding in Sun Pharma Adv. Res is 1.01% while previous quarter holding is 0.51%.